Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | original report

Prognostic factors and their correlation with staging in patients with multiple myeloma: a single centre study in North India

verfasst von: MD Tanvi Sood, MD Prof. Nirmal Yadav, MD Asst. Prof. Smita Gupta

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Background

Multiple myeloma is a neoplastic disorder characterised by proliferation of a single clone of plasma cells leading to varied clinical presentations. Various clinical and laboratory parameters have been established as prognostic factors but their correlation with staging systems has been sparingly studied in Indian population.

Methods

A retrospective study was done over a period of 30 months at a tertiary care centre including 33 patients of multiple myeloma. Physical examination, radiological investigations and routine laboratory investigations including bone marrow examination, serum protein electrophoresis and serum β2-microglobulin levels were recorded. Patients were staged according to the Durie–Salmon staging system (DSS) and the international staging system (ISS) and correlation between prognostic markers and clinical stage was studied.

Results

A total of 33 patients were included in the study, all of them had M-band in the gamma region on serum protein electrophoresis. Approximately, 51.5 % patients presented with renal failure and its presence correlated positively with the stage of disease (0.643, p < 0.001). Plasmacytosis showed a positive correlation with the stage of disease (0.351, p < 0.045). A significant positive correlation was also found between the DSS and ISS (0.575, p < 0.001). Haemoglobin, serum β2-microglobulin levels, advanced age, estimated sedimentation rate (ESR), serum creatinine and uraemia were other factors that significantly correlated with the clinical stage in our population.

Conclusion

Both ISS and DSS correlate well as staging systems for multiple myeloma in the Indian population. Routine investigations like haemoglobin, ESR, renal function tests and plasma cell percentage can be used for prognostication at initial presentation. Prognostic markers like serum β2-microglobulin and renal failure are strongly associated with more advanced stages of multiple myeloma.
Literatur
1.
Zurück zum Zitat Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010–2020) by cancer groups. Asian Pac J Cancer Prev. 2010;11:1045–9. PubMed Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010–2020) by cancer groups. Asian Pac J Cancer Prev. 2010;11:1045–9. PubMed
2.
Zurück zum Zitat The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57. CrossRef The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57. CrossRef
3.
Zurück zum Zitat Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54. CrossRefPubMed Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54. CrossRefPubMed
4.
Zurück zum Zitat Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20. CrossRefPubMed Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20. CrossRefPubMed
5.
Zurück zum Zitat Subramanian R, Basu D, Dutta TK. Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer. 2009;46(1):40–5. CrossRefPubMed Subramanian R, Basu D, Dutta TK. Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer. 2009;46(1):40–5. CrossRefPubMed
6.
Zurück zum Zitat Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55. PubMed Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55. PubMed
7.
Zurück zum Zitat Kaur P, Shah BS, Baja P. Multiple myeloma: a clinical and pathological profile. Gulf J Oncolog. 2014;1(16):14–20. PubMed Kaur P, Shah BS, Baja P. Multiple myeloma: a clinical and pathological profile. Gulf J Oncolog. 2014;1(16):14–20. PubMed
8.
Zurück zum Zitat Advani SH, Soman CS, Talwalkar GV, Lyer YS, Bhatia HM. Multiple-myeloma: review of 231 cases. Indian J Cancer. 1978;15(2):55–61. PubMed Advani SH, Soman CS, Talwalkar GV, Lyer YS, Bhatia HM. Multiple-myeloma: review of 231 cases. Indian J Cancer. 1978;15(2):55–61. PubMed
9.
Zurück zum Zitat Kumar L, Vikram P, Kochupillai V. Recent advances in the mangement of multiple myeloma. Natl Med J India. 2006;19(2):80–9. PubMed Kumar L, Vikram P, Kochupillai V. Recent advances in the mangement of multiple myeloma. Natl Med J India. 2006;19(2):80–9. PubMed
10.
Zurück zum Zitat Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. CrossRefPubMed Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. CrossRefPubMed
11.
Zurück zum Zitat Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol. 1994;87(4):832–4. CrossRefPubMed Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol. 1994;87(4):832–4. CrossRefPubMed
12.
Zurück zum Zitat Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med. 1967;42(6):937–48. CrossRefPubMed Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med. 1967;42(6):937–48. CrossRefPubMed
13.
Zurück zum Zitat Diwan AG, Gandhi SA, Krishna K, Shinde VP. Clinical profile of the spectrum of multiple myeloma in a teaching hospital. Med J DY Patil Univ. 2014;7:185–8. CrossRef Diwan AG, Gandhi SA, Krishna K, Shinde VP. Clinical profile of the spectrum of multiple myeloma in a teaching hospital. Med J DY Patil Univ. 2014;7:185–8. CrossRef
14.
Zurück zum Zitat Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29–40. PubMed Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29–40. PubMed
15.
Zurück zum Zitat Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990;150(8):1693–5. CrossRefPubMed Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990;150(8):1693–5. CrossRefPubMed
16.
Zurück zum Zitat Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N, Usha. Multiple myeloma–presenting as acute kidney injury. J Assoc Physicians India. 2009;57:23–6. Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N, Usha. Multiple myeloma–presenting as acute kidney injury. J Assoc Physicians India. 2009;57:23–6.
17.
Zurück zum Zitat Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889–93. CrossRefPubMed Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889–93. CrossRefPubMed
18.
Zurück zum Zitat Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail. 2000;22(4):465–77. CrossRefPubMed Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail. 2000;22(4):465–77. CrossRefPubMed
19.
Zurück zum Zitat Medical Research Council’s Working Party for Therapeutic Trials in Leukemia. Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance. Br J Haematol. 1973;24:123–39. CrossRef Medical Research Council’s Working Party for Therapeutic Trials in Leukemia. Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance. Br J Haematol. 1973;24:123–39. CrossRef
20.
Zurück zum Zitat Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985;52(1):1–6. PubMedCentralCrossRefPubMed Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985;52(1):1–6. PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J. Prognostic factors and staging systems of multiple myeloma. Chin Med J (Engl). 2007;120(19):1655–8. Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J. Prognostic factors and staging systems of multiple myeloma. Chin Med J (Engl). 2007;120(19):1655–8.
Metadaten
Titel
Prognostic factors and their correlation with staging in patients with multiple myeloma: a single centre study in North India
verfasst von
MD Tanvi Sood
MD Prof. Nirmal Yadav
MD Asst. Prof. Smita Gupta
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0225-5

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe